These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8768828)

  • 101. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time.
    Blackman MR
    Ann Intern Med; 2008 Nov; 149(9):677-9. PubMed ID: 18981489
    [No Abstract]   [Full Text] [Related]  

  • 102. Insulin-like growth factor I actions on steroidogenesis.
    Chatelain PG; Avallet MO; Nicolino M; Lejeune H; Clark A; Chuzel F; Penhoat A; Saez JM
    Acta Paediatr Suppl; 1994 Apr; 399():176-7. PubMed ID: 7949609
    [No Abstract]   [Full Text] [Related]  

  • 103. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
    Copinschi G; Leproult R; Van Onderbergen A; Caufriez A; Cole KY; Schilling LM; Mendel CM; De Lepeleire I; Bolognese JA; Van Cauter E
    Neuroendocrinology; 1997 Oct; 66(4):278-86. PubMed ID: 9349662
    [TBL] [Abstract][Full Text] [Related]  

  • 105. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
    Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
    J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
    Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
    J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
    Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
    J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.
    Thorner MO; Chapman IM; Gaylinn BD; Pezzoli SS; Hartman ML
    Recent Prog Horm Res; 1997; 52():215-44; discussion 244-6. PubMed ID: 9238854
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass.
    Gallagher D; Belmonte D; Deurenberg P; Wang Z; Krasnow N; Pi-Sunyer FX; Heymsfield SB
    Am J Physiol; 1998 Aug; 275(2):E249-58. PubMed ID: 9688626
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Orally active growth hormone secretagogues.
    Patchett AA; Smith RG; Wyvratt MJ
    Pharm Biotechnol; 1998; 11():525-54. PubMed ID: 9760695
    [No Abstract]   [Full Text] [Related]  

  • 112. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
    Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
    Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
    Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
    [TBL] [Abstract][Full Text] [Related]  

  • 118. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
    Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
    [TBL] [Abstract][Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.